Human Breast cancer suppressor candidate 1 (VWA5A) activation kit by CRISPRa

CAT#: GA102720

VWA5A CRISPRa kit - CRISPR gene activation of human von Willebrand factor A domain containing 5A



  See Other Versions

CNY 12,255.00


货期*
4周

规格
    • 1 kit

Product images

经常一起买 (3)
VWA5A mouse monoclonal antibody, clone OTI3D6 (formerly 3D6)
    • 100 ul

CNY 1,999.00
CNY 2,700.00


VWA5A (Myc-DDK-tagged)-Human von Willebrand factor A domain containing 5A (VWA5A), transcript variant 1
    • 10 ug

CNY 5,760.00
CNY 8,360.00


VWA5A mouse monoclonal antibody, clone OTI3B4 (formerly 3B4)
    • 30 ul

CNY 800.00

Specifications

Product Data
Format 3 gRNAs (5ug each), 1 scramble ctrl (10ug) and 1 enhancer vector (10ug)
Symbol VWA5A
Locus ID 4013
Kit Components

GA102720G1, Breast cancer suppressor candidate 1 gRNA vector 1 in pCas-Guide-GFP-CRISPRa

GA102720G2, Breast cancer suppressor candidate 1 gRNA vector 2 in pCas-Guide-GFP-CRISPRa

GA102720G3, Breast cancer suppressor candidate 1 gRNA vector 3 in pCas-Guide-GFP-CRISPRa

1 CRISPRa-Enhancer vector, SKU GE100056

1 CRISPRa scramble vector, SKU GE100077

Disclaimer These products are manufactured and supplied by OriGene under license from ERS. The kit is designed based on the best knowledge of CRISPRa SAM technology. The efficiency of the activation can be affected by many factors, including nucleosome occupancy status, chromatin structure and the gene expression level of the target, etc.
Reference Data
RefSeq NM_001130142, NM_014622, NM_198315
Synonyms BCSC-1; BCSC1; LOH11CR2A
Summary May play a role in tumorigenesis as a tumor suppressor. Altered expression of this protein and disruption of the molecular pathway it is involved in, may contribute directly to or modify tumorigenesis.[UniProtKB/Swiss-Prot Function]
*Delivery time may vary from web posted schedule. Occasional delays may occur due to unforeseen complexities in the preparation of your product. International customers may expect an additional 1-2 weeks in shipping.

Documents

Other Versions

Customer Reviews 
Loading...